Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BYL719|DRUG: LJM716|DRUG: TRASTUZUMAB
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Novartis